Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shareholders were treated to an unpleasant surprise by generics CEO Siggi Olafsson, who is said to be jumping ship.
Keep Reading →
December 7 - News, Stock Analysis
Immunomedics, Inc. (NASDAQ:IMMU) has a new drug candidate called IMMU-140 that is based on its antibody-drug conjugate (ADC) program.
Keep Reading →
December 7 - News, Stock Analysis
Tagrisso, a lung cancer med from AstraZeneca plc (ADR) (NYSE:AZN) is already in early approval based on mid-stage studies, which demonstrates the possibility of it replacing the...
Keep Reading →
December 7 - News, Stock Analysis
Right then, it’s time to take a look at who moved during the start of this week, and what’s driving the action in the biotech sector.
Keep Reading →
December 6 - Market Movers, News, Stock Analysis
Gregg Becker, who was the Chief Financial Officer at a clinic owned by Community Health, alleged in his suit that the company terminated his employment after he refused to alter...
Keep Reading →
December 6 - News, Stock Analysis
Biotech micro Cerecor Inc (NASDAQ:CERC) just put out mid stage data from its nicotine withdrawal trial, and things don’t look great.
Keep Reading →
December 6 - News, Stock Analysis
TherapeuticsMD Inc (NYSEMKT:TXMD) reported its candidate TX-001HR met expectations in a study dubbed the Replenish Trial, which tested the candidate against a placebo for treatment...
Keep Reading →
December 6 - News, Stock Analysis
AstraZeneca plc (ADR) (NYSE:AZN) plans to cut some back office jobs in the U.K. as the company works toward cost-cutting and operation consolidation.
Keep Reading →
December 6 - News, Stock Analysis
Sanofi SA (ADR) (NYSE:SNY) could spark a fierce bidding war for Actelion Ltd (OTCMKTS:ALIOF).
Keep Reading →
December 6 - News, Stock Analysis
One would think that a hepatitis B vaccine with 100% efficacy, negligible safety issues, and mountains of clinical data already supporting it would be valued at a little bit more...
Keep Reading →
December 6 - Hedge Funds, News, Stock Analysis
Uniqure NV (NASDAQ:QURE) just put out data from its lead hemophilia trial, and the company has taken a hit on the release.
Keep Reading →
December 5 - News, Stock Analysis
The National Institute for Health and Care Excellence (NICE) has confirmed the approval of a new injectable asthma drug from GlaxoSmithKline PLC (ADR) (NYSE:GSK).
Keep Reading →
December 2 - News, Stock Analysis
A number of small-cap biotech companies took a hit on their market capitalization on Thursday, but none more sharply than Aradigm Corporation (NASDAQ:ARDM).
Keep Reading →
December 2 - News, Stock Analysis
Individual lung cancer patients may soon be able to benefit from Keytruda, an immunotherapy drug from Merck & Co., Inc. (NYSE:MRK).
Keep Reading →
December 2 - News, Stock Analysis
Right then. It’s time to take a look at who is moving in the biotech space right now, and which of these movers are winners and which are winners.
Keep Reading →
December 1 - Market Movers, News, Stock Analysis
bluebird bio Inc (NASDAQ:BLUE) is up sharply pre market on Thursday, as the company put out fresh interim data from a phase I study of its multiple myeloma (MM) asset, bb2121.
Keep Reading →
December 1 - News, Stock Analysis
Gilead Sciences, Inc. (NASDAQ:GILD) has switched course and has begun aggressive marketing of its HIV drug Truvada as a preventative medicine for HIV-negative healthy people.
Keep Reading →
December 1 - News, Stock Analysis
Buyout talks between Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) that would have resulted in the sale of Salix Pharmaceuticals...
Keep Reading →
December 1 - News, Stock Analysis
Manufacturing problems in France threaten to delay the release of Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN)'s blockbuster drug, dupilumab, according...
Keep Reading →
November 30 - News, Stock Analysis
GlaxoSmithKline plc (ADR) (NYSE:GSK) has moved to expand the target market for its blockbuster vaccine, Shingrix, with the filing of a regulatory application in Europe.
Keep Reading →
November 30 - News, Stock Analysis
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) just shocked markets with the announcement that it would be discontinuing its lead development programs.
Keep Reading →
November 30 - News, Stock Analysis
It’s time to take a look at those stocks that really moved over the last twenty-four hours or so in biotech, and there are plenty to go at.
Keep Reading →
November 29 - Market Movers, News, Stock Analysis
Recro Pharma Inc (NASDAQ:REPH) is one of the week's runners in biotech so far. The company just put out data from a late stage trial and gained more than 20% on the news.
Keep Reading →
November 29 - News, Stock Analysis
Gilead Sciences, Inc. (NASDAQ:GILD) might as well have quashed rumors making waves claiming it is planning to acquire Belgium-based Galapagos NV (ADR) (NASDAQ:GLPG).
Keep Reading →
November 29 - News, Stock Analysis
We’ve had a big start to the week in biotech, as a number of companies pick up trading after the Thanksgiving break in the US, and this resumption of trading has translated ...
Keep Reading →
November 28 - Market Movers, News, Stock Analysis
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) just announced the submission of its New Drug Application (NDA) for Rexista, it’s bioequivalent OxyContin product.
Keep Reading →
November 28 - News, Stock Analysis
Mateon Therapeutics Inc (NASDAQ:MATN) has spent the last few months petitioning its shareholders for approval of a reverse split.
Keep Reading →
November 25 - News, Stock Analysis
As the markets take a break for Thanksgiving, things settled down a little bit late-Wednesday, but not before some sharp shocks in the biotech sector.
Keep Reading →
November 24 - Market Movers, News, Stock Analysis
Galapagos NV (ADR) (NASDAQ:GLPG) just updated the markets as to the status of a couple of its lead development programs, and while the company hasn’t really moved on the update...
Keep Reading →
November 23 - News, Stock Analysis
In most cases a new method of drug delivery can occasionally alter markets a bit and cause some shifts. In rare cases though, it can fundamentally change an entire sector.
Keep Reading →
November 23 - News, Stock Analysis
The 1st US Circuit Court of Appeals has recently ruled in favor of AstraZeneca plc (ADR) (NYSE:AZN) and Ranbaxy Laboratories Limited (ADR) (OTCMKTS:RBXLY) on a long-lasting class...
Keep Reading →
November 23 - News, Stock Analysis
The US Food and Drug Administration (FDA) has recently approved the Soliqua 100/33 (insulin glargine and lixisenatide injection) of Sanofi SA (ADR) (NYSE:SNY) and the Xultophy...
Keep Reading →
November 23 - News, Stock Analysis
To find a winner in the biotech space this week, all you’d need to do is throw a dart at a basket of micro-caps.
Keep Reading →
November 22 - Market Movers, News, Stock Analysis
Novartis AG (ADR) (NYSE:NVS) has recently acquired Selexys Pharmaceuticals Corp.
Keep Reading →
November 22 - News, Stock Analysis
Theravance Biopharma Inc (NASDAQ:TBPH) just put out an announcement relating to its closed triple asset, and the company is trading flat-to-down despite the seemingly positive...
Keep Reading →
November 22 - News, Stock Analysis
GlobeImmune Inc (OTCMKTS:GBIM) shareholders did not have a good week last week.
Keep Reading →
November 21 - News, Stock Analysis
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) soared throughout the US session on Thursday, gaining as much as 60% across the day.
Keep Reading →
November 18 - News, Stock Analysis
OpGen Inc (NASDAQ:OPGN), a Market Exclusive favorite, earlier this week announced that it is bolstering its already long-standing relationship with pharmaceutical giant Merck...
Keep Reading →
November 17 - News, Stock Analysis
We’ve had another big day in biotech, and a number of companies have moved on news and fundamental developments.
Keep Reading →
November 17 - Market Movers, News, Stock Analysis
TESARO Inc (NASDAQ:TSRO) just announced an equity offering, and the company has taken a considerable hit as a result.
Keep Reading →
November 16 - News, Stock Analysis
Pfizer Inc. (NYSE:PFE) has confirmed its collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), on immunotherapy development.
Keep Reading →
November 16 - News, Stock Analysis
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is alleged to have bought its way into boosting its sales in foreign countries including Russia, Mexico, and Ukraine.
Keep Reading →
November 16 - News, Stock Analysis
Last week was a wild ride for a number of companies in the biotech space, with the U.S election bringing with it an initial wave of uncertainty, followed by the realization that...
Keep Reading →
November 15 - Market Movers, News, Stock Analysis
Puma Biotechnology Inc (NYSE:PBYI) just announced its abstract for an upcoming 2016 San Antonio Breast Cancer Symposium (SABCS), which will take place on December 6 – 10, 2016...
Keep Reading →
November 15 - News, Stock Analysis
The US Food and Drug Administration (FDA) has recently granted Medtronic PLC (NYSE:MDT) the approval for the Claria Magnetic Resonance Imaging (MRI) Quad Cardiac Resynchronization...
Keep Reading →
November 15 - News, Stock Analysis
Dimension Therapeutics Inc (NASDAQ:DMTX) reported at the end of last week that it will present data from its phase 1/2 clinical trial of DTX101 for the treatment of hemophilia...
Keep Reading →
November 14 - News, Stock Analysis
